These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 33094918)

  • 41. Dosing depending on SIRT3 activity attenuates doxorubicin-induced cardiotoxicity via elevated tolerance against mitochondrial dysfunction and oxidative stress.
    Yang N; Ma H; Jiang Z; Niu L; Zhang X; Liu Y; Wang Y; Cheng S; Deng Y; Qi H; Wang Z
    Biochem Biophys Res Commun; 2019 Sep; 517(1):111-117. PubMed ID: 31303273
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early and late onset cardiotoxicity following anthracycline-based chemotherapy in breast cancer patients: Incidence and predictors.
    Serrano JM; Mata R; González I; Del Castillo S; Muñiz J; Morales LJ; Espinosa MJ; Moreno F; Jiménez R; Cristobal C; Graupner C; Talavera P; Landaluce CG; Curcio A; Alonso J; Guerra JA; Alonso JJ
    Int J Cardiol; 2023 Jul; 382():52-59. PubMed ID: 37080467
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Peroxiredoxin-1 Overexpression Attenuates Doxorubicin-Induced Cardiotoxicity by Inhibiting Oxidative Stress and Cardiomyocyte Apoptosis.
    Jiang L; Gong Y; Hu Y; You Y; Wang J; Zhang Z; Wei Z; Tang C
    Oxid Med Cell Longev; 2020; 2020():2405135. PubMed ID: 32802259
    [No Abstract]   [Full Text] [Related]  

  • 44. Variation in RARG increases susceptibility to doxorubicin-induced cardiotoxicity in patient specific induced pluripotent stem cell-derived cardiomyocytes.
    Christidi E; Huang H; Shafaattalab S; Maillet A; Lin E; Huang K; Laksman Z; Davis MK; Tibbits GF; Brunham LR
    Sci Rep; 2020 Jun; 10(1):10363. PubMed ID: 32587261
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Protease-activated receptor 1 activation enhances doxorubicin-induced cardiotoxicity.
    Antoniak S; Tatsumi K; Schmedes CM; Grover SP; Pawlinski R; Mackman N
    J Mol Cell Cardiol; 2018 Sep; 122():80-87. PubMed ID: 30098988
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study.
    Gavila J; Seguí MÁ; Calvo L; López T; Alonso JJ; Farto M; Sánchez-de la Rosa R
    Clin Transl Oncol; 2017 Jan; 19(1):91-104. PubMed ID: 27101413
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Induction of P-glycoprotein expression by dandelion in tumor and heart tissues: Impact on the anti-tumor activity and cardiotoxicity of doxorubicin.
    Qu J; Ke F; Yang X; Wang Y; Xu H; Li Q; Bi K
    Phytomedicine; 2022 Sep; 104():154275. PubMed ID: 35760022
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interleukin-10 Levels are Associated with Doxorubicin-Related Cardiotoxicity in Breast Cancer Patients in a One-Year Follow-Up Study.
    Alves MT; Simões R; Pestana RMC; de Oliveira AN; Oliveira HHM; Soares CE; Sabino AP; Silva LM; Gomes KB
    Immunol Invest; 2022 May; 51(4):883-898. PubMed ID: 33557640
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mitochondrial-Targeted Therapy for Doxorubicin-Induced Cardiotoxicity.
    Wu BB; Leung KT; Poon EN
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163838
    [TBL] [Abstract][Full Text] [Related]  

  • 50. AKR1B1 inhibition using NARI-29-an Epalrestat analogue-alleviates Doxorubicin-induced cardiotoxicity via modulating Calcium/CaMKII/MuRF-1 axis.
    Syamprasad NP; Jain S; Rajdev B; Panda SR; Gangasani JK; Challa VS; Vaidya JR; Kundu GC; Naidu VGM
    Chem Biol Interact; 2023 Aug; 381():110566. PubMed ID: 37257577
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes as an in vitro model in toxicology: strengths and weaknesses for hazard identification and risk characterization.
    Burnett SD; Blanchette AD; Chiu WA; Rusyn I
    Expert Opin Drug Metab Toxicol; 2021 Aug; 17(8):887-902. PubMed ID: 33612039
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: study protocol for a pilot, randomized, double-blind, controlled trial (CarDHA trial).
    Carrasco R; Ramirez MC; Nes K; Schuster A; Aguayo R; Morales M; Ramos C; Hasson D; Sotomayor CG; Henriquez P; Cortés I; Erazo M; Salas C; Gormaz JG
    Trials; 2020 Feb; 21(1):137. PubMed ID: 32019575
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Paradoxically, iron overload does not potentiate doxorubicin-induced cardiotoxicity in vitro in cardiomyocytes and in vivo in mice.
    Guenancia C; Li N; Hachet O; Rigal E; Cottin Y; Dutartre P; Rochette L; Vergely C
    Toxicol Appl Pharmacol; 2015 Apr; 284(2):152-62. PubMed ID: 25711856
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An update of the molecular mechanisms underlying doxorubicin plus trastuzumab induced cardiotoxicity.
    Anjos M; Fontes-Oliveira M; Costa VM; Santos M; Ferreira R
    Life Sci; 2021 Sep; 280():119760. PubMed ID: 34166713
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HER2+ breast cancer treatment and cardiotoxicity: monitoring and management.
    Jerusalem G; Lancellotti P; Kim SB
    Breast Cancer Res Treat; 2019 Sep; 177(2):237-250. PubMed ID: 31165940
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ginsenoside Rh2 mitigates doxorubicin-induced cardiotoxicity by inhibiting apoptotic and inflammatory damage and weakening pathological remodelling in breast cancer-bearing mice.
    Hou J; Yun Y; Cui C; Kim S
    Cell Prolif; 2022 Jun; 55(6):e13246. PubMed ID: 35534947
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity.
    Reynolds JG; Geretti E; Hendriks BS; Lee H; Leonard SC; Klinz SG; Noble CO; Lücker PB; Zandstra PW; Drummond DC; Olivier KJ; Nielsen UB; Niyikiza C; Agresta SV; Wickham TJ
    Toxicol Appl Pharmacol; 2012 Jul; 262(1):1-10. PubMed ID: 22676972
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tissue-specific regulation of p53 by PKM2 is redox dependent and provides a therapeutic target for anthracycline-induced cardiotoxicity.
    Saleme B; Gurtu V; Zhang Y; Kinnaird A; Boukouris AE; Gopal K; Ussher JR; Sutendra G
    Sci Transl Med; 2019 Feb; 11(478):. PubMed ID: 30728290
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Polymorphic Variations Associated With Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients.
    Todorova VK; Makhoul I; Dhakal I; Wei J; Stone A; Carter W; Owen A; Klimberg VS
    Oncol Res; 2017 Sep; 25(8):1223-1229. PubMed ID: 28256194
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
    Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
    Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.